Is Coronary Artery Calcium Testing the Best Way to Decide on Statins?

Dr. Kumar’s Take:

A recent study from the Multi-Ethnic Study of Atherosclerosis (MESA) suggests that coronary artery calcium (CAC) testing can help doctors make better decisions about who should take statins. Instead of giving statins to all intermediate-risk patients, CAC testing allows doctors to focus treatment on those who truly need it, potentially reducing unnecessary medication use and side effects.

If you’re at intermediate risk for heart disease, getting a CAC test could help you and your doctor make a more informed decision about statin therapy. It may be a cost-effective way to prevent heart disease while avoiding unnecessary medication.

Read more

LDL Cholesterol and Heart Disease: What Your Calcium Score Tells You

Dr. Kumar’s Take:

A recent study from the Western Denmark Heart Registry sheds light on how LDL cholesterol (LDL-C) contributes to heart disease. The key takeaway? If you don’t have coronary artery calcification (CAC), your LDL levels may not be as dangerous as previously thought. However, if CAC is present, high LDL-C significantly raises your risk of heart attack or stroke. This research could reshape how we assess cardiovascular risk and who truly benefits from aggressive cholesterol-lowering treatment.

Read more

LDL Cholesterol: Finding the Right Balance for Heart Health

Dr. Kumar’s Take

This study looked at how different levels of LDL cholesterol affect our chance of dying from any cause and from heart-related problems. It found that having very low or very high LDL can be risky, but in different ways.

• Very low LDL (<70 mg/dL) was linked to a higher risk of strokes and overall heart-related deaths (cardiovascular mortality).
• Very high LDL (≥190 mg/dL) was linked to a higher risk of heart disease (CHD) and overall heart-related deaths, but it did not show an increase in deaths from any cause (all-cause mortality).

In other words, both very low and very high LDL levels increase the risk of heart problems. However, very high LDL does not increase the overall chance of dying when compared to moderate LDL levels.

Read more

Should You Take a Statin if Your LDL is High on a Low-Carb Diet?

Dr. Kumar’s Take:

This study challenges the long-held belief that LDL-C (low-density lipoprotein cholesterol) is always harmful. The authors argue that in the context of a low-carbohydrate diet (LCD), high LDL-C may not be a sign of increased cardiovascular disease (CVD) risk. Instead, they suggest looking at other markers—such as insulin resistance, triglyceride-to-HDL ratio, and coronary artery calcium (CAC) score—before deciding whether statins are necessary.

For those on an low carbohydrate diet with high LDL-C but otherwise good metabolic markers (low triglycerides, high HDL), this study suggests that statins may not provide the same benefits as they do for those with high LDL-C caused by poor diet and metabolic disease.

Read more

Understanding Cholesterol and Cardiovascular Risk: The Full Picture

Dr. Kumar’s Take:

A recent systematic review and meta-analysis examined the relationship between cholesterol levels and cardiovascular mortality. While the study confirmed that higher total cholesterol (TC) and low-density lipoprotein (LDL-C) increase the risk of cardiovascular death, it’s crucial to look beyond relative risk. The absolute risk increase remains small, meaning that while cholesterol levels do play a role in cardiovascular health, they may not be as dangerous as they seem at first glance.

Read more

Does Vitamin D Supplementation Reduce Heart Disease Risk?

Dr. Kumar’s Take:

A recent study investigated whether taking high-dose vitamin D could lower the risk of major heart-related events like heart attacks and strokes. The results suggest a small potential benefit, particularly for people already taking medications for heart health. However, the overall impact was modest, and more research is needed before vitamin D can be recommended as a heart-protective supplement.

Brief Summary:

The D-Health Trial was a large, randomized, double-blind, placebo-controlled study conducted in Australia. It followed 21,315 adults aged 60-84 years over five years to determine if monthly high-dose vitamin D (60,000 IU) could reduce major cardiovascular events like heart attacks, strokes, and coronary procedures.

Read more

Omega-3 Fatty Acids and Longevity: A Comprehensive Meta-Analysis

Dr. Kumar’s Take:

This extensive meta-analysis, pooling data from 17 cohort studies and over 42,000 individuals, provides compelling evidence that higher blood levels of long-chain omega-3 fatty acids—EPA, DPA, and DHA—are associated with a reduced risk of all-cause mortality. The study highlights that individuals in the highest quintile of omega-3 levels had a 15-18% lower risk of death compared to those in the lowest quintile. These findings reinforce the importance of incorporating omega-3-rich foods like fatty fish or supplements into a health-conscious lifestyle.

Read more

Omega-3 Fatty Acids for Hypertriglyceridemia: AHA's Latest Science Advisory

Dr. Kumar’s Take:

The American Heart Association (AHA) has reinforced the role of omega-3 fatty acids in managing hypertriglyceridemia (high triglycerides), with updated insights on EPA-only vs. EPA+DHA formulations. This review supports the use of 4g/day prescription n-3 FAs for triglyceride reduction and highlights cardiovascular benefits observed in key trials.

Brief Summary:

This comprehensive AHA science advisory evaluates the efficacy, safety, and clinical implications of omega-3 fatty acids for hypertriglyceridemia management. The review highlights that prescription doses (≥4 g/day) of n-3 FAs, whether EPA-only or EPA+DHA, can lower triglycerides by 20–30% in individuals with moderately high triglycerides (200–499 mg/dL) and ≥30% in those with very high triglycerides (≥500 mg/dL). The REDUCE-IT trial showed a 25% reduction in major adverse cardiovascular events with EPA-only therapy in high-risk patients. While EPA-only formulations appear neutral on LDL-C, EPA+DHA may increase LDL-C in some cases.

Read more

Optimal Omega-3 Intake for Blood Pressure Reduction: What the Science Says

Dr. Kumar’s Take:

A meta-analysis of 71 randomized controlled trials (RCTs) provides strong evidence that omega-3 polyunsaturated fatty acids (PUFAs) can lower blood pressure (BP). The study found that a combined daily intake of 2 to 3 grams of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) offers the most significant BP reductions. This is particularly beneficial for individuals with hypertension or hyperlipidemia, who may experience an even stronger response. If you’re looking to support heart health, optimizing your omega-3 intake could be a simple yet effective strategy.

Read more

The Cardiometabolic Effects of Long-Chain Omega-3s: Are They Worth It?

Dr. Kumar’s Take:

Recent research into long-chain omega-3 polyunsaturated fatty acids (LC ω-3 PUFAs) presents a mixed picture. While supplementation with EPA and DHA shows promise in reducing triglycerides and improving certain cardiovascular outcomes, inconsistencies in trial results highlight the need for a nuanced approach. The REDUCE-IT trial suggests strong cardiovascular benefits for high-dose EPA, while the STRENGTH trial, which studied EPA/DHA combinations, showed no significant reduction in cardiovascular events. One notable concern is the increased risk of atrial fibrillation observed across multiple studies. For those considering omega-3 supplementation, EPA alone may be a more effective and targeted choice, especially for individuals with elevated triglycerides.

Read more